{"id":78420,"date":"2026-03-12T12:05:14","date_gmt":"2026-03-12T12:05:14","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/"},"modified":"2026-03-12T12:05:14","modified_gmt":"2026-03-12T12:05:14","slug":"mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/","title":{"rendered":"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia"},"content":{"rendered":"<div>\n<p align=\"justify\">CAMBRIDGE, United Kingdom, March  12, 2026  (GLOBE NEWSWIRE) &#8212; Mestag Therapeutics (\u201cMestag\u201d), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announced today that it will be presenting a poster at the Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications &amp; Combinations Keystone Symposia taking place March 15-18, 2026, in Qu\u00e9bec City, Canada, titled \u201cMST-0312: FAP-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors.\u201d<\/p>\n<p align=\"justify\"><strong>Poster Details: <\/strong><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"width:161.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Title:<\/td>\n<td style=\"width:509.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">MST-0312: FAP-targeted LTBR Agonist Induces High Endothelial Venules, Lymphocyte Infiltration and Tertiary Lymphoid Structures in Solid Tumors<\/td>\n<\/tr>\n<tr>\n<td style=\"width:161.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Poster Number:<\/td>\n<td style=\"width:509.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1037<\/td>\n<\/tr>\n<tr>\n<td style=\"width:161.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Date:<\/td>\n<td style=\"width:509.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">March 16, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:161.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Time:<\/td>\n<td style=\"width:509.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1:00-3:00 p.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"width:161.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Session Title:<\/td>\n<td style=\"width:509.67px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Poster Session 1<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>About MST-0312<\/strong><br \/>MST-0312 is a first-in-class targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures (TLS) and high endothelial venules (HEV) in solid tumors. A remarkable body of clinical evidence correlates the presence of TLS and HEV in tumors with improved response to treatment and patient survival outcomes. It is believed that TLS\/HEV formation drives improved access of lymphocytes into tumor tissue, and facilitates local education and activation to tumor antigens. LTBR is the key pathway driving TLS\/HEV formation. Preclinical studies show that MST-0312 monotherapy induces strong, dose-dependent anti-tumor responses, including in low-antigen tumors that are typically resistant to immunotherapy. MST-0312 is planned to enter the clinic in 2026 with the initiation of the Phase 1 STARLYS trial, advised by leading cancer experts.<\/p>\n<p align=\"justify\"><strong>About Mestag Therapeutics<\/strong><br \/>Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a unique pipeline of novel antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology.<\/p>\n<p align=\"justify\">Our pipeline includes MST-0312, a FAP-targeted LTBR agonist bispecific antibody that leverages a new understanding of tertiary lymphoid structures (TLSs) in solid tumors and their role in driving improved patient outcomes; the M402 program, an agonist antibody targeting a stromal inhibitory receptor to dampen down the activation of specific immune cell subsets in inflammatory disease; and earlier programs in discovery stage.<\/p>\n<p align=\"justify\">Separately, we are also identifying novel targets for future therapies utilizing our specialist fibroblast-immune RAFT Platform. In 2024, we entered into a license and research collaboration with MSD (tradename of Merck &amp; Co., Inc., Rahway, N.J., USA) to identify novel targets for inflammatory diseases, and licensed a novel target to Johnson &amp; Johnson under a 2021 target discovery, option and license agreement with Janssen Biotech, Inc.<\/p>\n<p align=\"justify\">Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham &amp; Women\u2019s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. Mestag was founded by SV Health Investors and is supported by leading life science investors Johnson &amp; Johnson Innovation \u2013 JJDC, Inc., Forbion, GV (Google Ventures) and Northpond Ventures.<\/p>\n<p align=\"justify\">For further information, please visit our website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cL2STUJzGrirVdKSvfEaOWAhWweqfLRLZbW8bd2peWOo085jt-dFU3VA7tPtcNlRnGHFle3DNXWzY5-4D0J-CoWLCAG_tYVZHaFjnIw-wUq-m1By6JJ_6-anCypXKXpK\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.mestagtherapeutics.com<\/u><\/a>.<\/p>\n<p>For enquiries, please contact:<\/p>\n<p align=\"justify\">Investors<br \/>Alexandra Santos<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cUatq1dzIEgRfgrqZJsGClGq7rGImp97pAQFfikruOL1VjfIZHEUkml7VYko5pcUuN3lEAskdWNV6ZKBYrlfpibmRI0eVVxZmq1pqhIk998U_4iIP5S7U4GzyTi53y_m\" rel=\"nofollow\" target=\"_blank\" title=\"asantos@wheelhouselsa.com\">asantos@wheelhouselsa.com<\/a><\/p>\n<p align=\"justify\">Media<br \/>Aljanae Reynolds<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LmGiRyptFN-B-J6mE-rE_e02YZiI2c0uRuFHWMPJ-PRXdy-7M2rPAue7hjtvtBJ83Ncvaxw9YQoBCf7ZdjSIaahHnpREQfCZoyNthQNKImff5lwzU2z_P3OjZB-Y_Ces\" rel=\"nofollow\" target=\"_blank\" title=\"areynolds@wheelhouselsa.com\">areynolds@wheelhouselsa.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YTlkZGVkZmMtNDAzZS00NTdlLTgxZGEtYmM2MTQ2YzUzM2UyLTEyOTc0OTAtMjAyNi0wMy0xMi1lbg==\/tiny\/Mestag-Therapeutics-Ltd-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) &#8212; Mestag Therapeutics (\u201cMestag\u201d), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announced today that it will be presenting a poster at the Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications &amp; Combinations Keystone Symposia taking place March 15-18, 2026, [&#8230;]\n","protected":false},"author":1,"featured_media":78421,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-78420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) &#8212; Mestag Therapeutics (\u201cMestag\u201d), a biotech company harnessing fibroblast immunol\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T12:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/YTlkZGVkZmMtNDAzZS00NTdlLTgxZGEtYmM2MTQ2YzUzM2UyLTEyOTc0OTAtMjAyNi0wMy0xMi1lbg==\/tiny\/Mestag-Therapeutics-Ltd-.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia\",\"datePublished\":\"2026-03-12T12:05:14+00:00\",\"dateModified\":\"2026-03-12T12:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\"},\"wordCount\":506,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\",\"name\":\"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-03-12T12:05:14+00:00\",\"dateModified\":\"2026-03-12T12:05:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/","og_locale":"en_US","og_type":"article","og_title":"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia","og_description":"CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) &#8212; Mestag Therapeutics (\u201cMestag\u201d), a biotech company harnessing fibroblast immunol","og_url":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-03-12T12:05:14+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/YTlkZGVkZmMtNDAzZS00NTdlLTgxZGEtYmM2MTQ2YzUzM2UyLTEyOTc0OTAtMjAyNi0wMy0xMi1lbg==\/tiny\/Mestag-Therapeutics-Ltd-.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia","datePublished":"2026-03-12T12:05:14+00:00","dateModified":"2026-03-12T12:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/"},"wordCount":506,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/","url":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/","name":"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-03-12T12:05:14+00:00","dateModified":"2026-03-12T12:05:14+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/mestag-therapeutics-to-present-data-on-targeted-ltbr-agonist-mst-0312-at-cancer-immunotherapy-keystone-symposia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=78420"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/78421"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=78420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=78420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=78420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}